Credit Suisse Group reissued their outperform rating on shares of TESARO (NASDAQ:TSRO) in a research report report published on Thursday morning, MarketBeat reports. Credit Suisse Group currently has a $150.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $190.00.

Several other equities research analysts also recently weighed in on TSRO. Robert W. Baird reissued a neutral rating and set a $125.00 price target on shares of TESARO in a research report on Monday, October 2nd. ValuEngine downgraded shares of TESARO from a hold rating to a sell rating in a research report on Tuesday, October 10th. HC Wainwright started coverage on shares of TESARO in a research report on Thursday, October 12th. They set a buy rating and a $158.00 price target for the company. Zacks Investment Research downgraded shares of TESARO from a hold rating to a sell rating in a research report on Tuesday, October 17th. Finally, Barclays started coverage on shares of TESARO in a research report on Monday, October 23rd. They set an equal weight rating and a $135.00 price target for the company. Three analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $149.97.

TESARO (NASDAQ TSRO) traded up $0.41 during mid-day trading on Thursday, hitting $63.91. 1,291,750 shares of the stock traded hands, compared to its average volume of 1,072,776. TESARO has a 1 year low of $59.77 and a 1 year high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm’s quarterly revenue was up 740.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.72) earnings per share. sell-side analysts predict that TESARO will post -8.19 EPS for the current year.

In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 40.50% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Hanseatic Management Services Inc. grew its position in TESARO by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 5,936 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 15 shares during the period. Stephens Inc. AR grew its position in TESARO by 6.5% in the 2nd quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 115 shares during the period. Cornerstone Capital Management Holdings LLC. grew its position in TESARO by 1.1% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 12,092 shares of the biopharmaceutical company’s stock worth $1,690,000 after purchasing an additional 136 shares during the period. KBC Group NV grew its position in TESARO by 10.9% in the 3rd quarter. KBC Group NV now owns 5,606 shares of the biopharmaceutical company’s stock worth $724,000 after purchasing an additional 553 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its position in TESARO by 1.2% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 49,054 shares of the biopharmaceutical company’s stock worth $6,333,000 after purchasing an additional 570 shares during the period.

TRADEMARK VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/01/21/tesaro-tsro-given-outperform-rating-at-credit-suisse-group.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.